SearchNewsletter

Search

Results for “farxiga”

Drug facts and side effects, recalls, research, clinical trials and medical reference, from the FDA, the National Library of Medicine and this site.

Drug lookup

Dapagliflozin (Farxiga)

Label from Astrazeneca Pharmaceuticals LP

  • Not on the FDA shortage list
  • No recalls in the last 3 years

What it is used for

FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

How it comes

Tablets: • 5 mg, yellow, biconvex, round, film-coated tablets with “5” engraved on one side and “1427” engraved on the other side. • 10 mg, yellow, biconvex, diamond-shaped, film-coated tablets with “10” engraved on one side and “1428” engraved on the other side. • Tablets: 5 mg and 10 mg ( 3 )

Full prescribing information (DailyMed) (opens in a new tab) Patient information (MedlinePlus) (opens in a new tab)

From the FDA drug label and openFDA records. For reference, not medical advice.

Most-reported side effects

60,090 reports to the FDA

  1. Death8,149
  2. Nausea2,683
  3. Fatigue2,675
  4. Diarrhoea2,496
  5. Dizziness2,428
  6. Dyspnoea2,272
  7. Blood glucose increased2,186
  8. Off label use2,161
  9. Weight decreased2,144
  10. Vomiting1,990

From the FDA Adverse Event Reporting System. These are voluntary reports: they do not show that the drug caused the event, or how often it happens.

Research

4,648 articles in PubMed, most relevant first

  1. Randomized trial2023 · European journal of heart failure

    Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial (opens in a new tab)

    Chatur S, Cunningham JW, Vaduganathan M, et al.

  2. Review2019 · DrugsFree full text

    Dapagliflozin: A Review in Type 2 Diabetes (opens in a new tab)

    Dhillon S

  3. Systematic review2023 · ESC heart failureFree full text

    Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods (opens in a new tab)

    Chen HB, Yang YL, Meng RS, et al.

  4. Randomized trial2024 · Journal of the American College of Cardiology

    Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure (opens in a new tab)

    Cox ZL, Collins SP, Hernandez GA, et al.

  5. Randomized trial2021 · Journal of the American Society of Nephrology : JASNFree full text

    Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease (opens in a new tab)

    Chertow GM, Vart P, Jongs N, et al.

  6. Randomized trial2021 · Kidney international

    A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (opens in a new tab)

    Wheeler DC, Toto RD, Stefánsson BV, et al.

See all 4,648 on PubMed (opens in a new tab)

Clinical trials

777 studies on ClinicalTrials.gov

  1. CompletedPhase 4 · started 2019

    SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease (opens in a new tab)

    Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

  2. TerminatedPhase 4 · started 2022

    Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients (opens in a new tab)

    Centre Hospitalier Universitaire Saint Pierre

  3. Active not recruitingPhase 3 · started 2024

    Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (opens in a new tab)

    Kirby Institute

  4. Completedstarted 2020

    Glucose-homeostasis After Endoscopic Sleeve Gastroplasty (opens in a new tab)

    Insel Gruppe AG, University Hospital Bern

  5. CompletedPhase 4 · started 2016

    Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (opens in a new tab)

    M.H.H. Kramer

  6. WithdrawnPhase 4 · started 2021

    Dapagliflozin Effect on Erythropoiesis and Physical Fitness (opens in a new tab)

    University Hospital Tuebingen

See all 777 on ClinicalTrials.gov (opens in a new tab)

Medical reference

StatPearls, for clinicians

  1. Sodium-Glucose Transport 2 (SGLT2) Inhibitors (opens in a new tab)

  2. Heart Failure With Preserved Ejection Fraction (HFpEF) (opens in a new tab)

  3. Secondary Hypertension (opens in a new tab)

  4. Management of Cardiovascular and Diabetes Risks Based on National Guidelines (opens in a new tab)

See all 45 StatPearls chapters (opens in a new tab)

Research, trials and reference come from the National Library of Medicine (PubMed, ClinicalTrials.gov, StatPearls on the NCBI Bookshelf, MedlinePlus); drug facts, side-effect reports and recalls from the FDA. For reference, not medical advice.